Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

May 20, 2025

Primary Completion Date

May 20, 2027

Study Completion Date

May 20, 2030

Conditions
Metastatic Breast Cancer
Interventions
GENETIC

Liquid Biopsy

Patients with metastatic breast cancer in disease progression will undergo a liquid biopsy

GENETIC

Archival Tumor DNA

Patients will be prompted to request an archival tumor sample from metastatic origin (preferably) and to send it to the central laboratory for analysis

Trial Locations (1)

08008

RECRUITING

SOLTI Cancer Research Group, Barcelona

Sponsors
All Listed Sponsors
collaborator

Roche Farma, S.A

INDUSTRY

collaborator

Menarini Group

INDUSTRY

collaborator

AstraZeneca

INDUSTRY

collaborator

Pfizer

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

SOLTI Breast Cancer Research Group

OTHER